Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1991 Mar 1;173(3):647–658. doi: 10.1084/jem.173.3.647

Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes

PMCID: PMC2118834  PMID: 1900079

Abstract

We have investigated the mechanisms whereby adoptively transferred murine CD8+ lymphocytes mediate tumor regressions. Noncytolytic, CD8+ tumor-infiltrating lymphocytes (TIL) eradicated established lung tumors in irradiated mice. Many cytolytic and noncytolytic CD8+ TIL cultures specifically secreted interferon gamma (IFN-gamma) and tumor necrosis factor when stimulated with tumor cells in vitro. The effectiveness of TIL when adoptively transferred to mice bearing micrometastases correlated better with their ability to specifically secrete lymphokines than with their cytotoxicity in vitro. In 14 of 15 tests, therapeutically effective TIL specifically secreted IFN-gamma in vitro, whereas only 1 of 11 ineffective TIL specifically secreted IFN-gamma. In contrast, only 8 of 15 therapeutically effective TIL were cytolytic. Antibodies to TNF inhibited the effectiveness of two adoptively transferred TIL cultures. In five experiments, antibodies to IFN-gamma abrogated the ability of four different CD8+ TIL cultures to mediate tumor regressions, indicating that secretion of IFN-gamma is an essential part of the mechanism of action of TIL.

Full Text

The Full Text of this article is available as a PDF (1.1 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson R. E., Warner N. L. Ionizing radiation and the immune response. Adv Immunol. 1976;24:215–335. doi: 10.1016/s0065-2776(08)60331-4. [DOI] [PubMed] [Google Scholar]
  2. Barth R. J., Jr, Bock S. N., Mulé J. J., Rosenberg S. A. Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes. J Immunol. 1990 Feb 15;144(4):1531–1537. [PubMed] [Google Scholar]
  3. Bhan A. K., Perry L. L., Cantor H., McCluskey R. T., Benacerraf B., Greene M. I. The role of T cell sets in the rejection of a methylcholanthrene-induced sarcoma (S1509a) in syngeneic mice. Am J Pathol. 1981 Jan;102(1):20–27. [PMC free article] [PubMed] [Google Scholar]
  4. Buchmeier N. A., Schreiber R. D. Requirement of endogenous interferon-gamma production for resolution of Listeria monocytogenes infection. Proc Natl Acad Sci U S A. 1985 Nov;82(21):7404–7408. doi: 10.1073/pnas.82.21.7404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chauvenet P. H., McArthur C. P., Smith R. T. Demonstration in vitro of cytotoxic T cells with apparent specificity toward tumor-specific transplantation antigens on chemically induced tumors. J Immunol. 1979 Dec;123(6):2575–2581. [PubMed] [Google Scholar]
  6. Dailey M. O., Pillemer E., Weissman I. L. Protection against syngeneic lymphoma by a long-lived cytotoxic T-cell clone. Proc Natl Acad Sci U S A. 1982 Sep;79(17):5384–5387. doi: 10.1073/pnas.79.17.5384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fernandez-Cruz E., Halliburton B., Feldman J. D. In vivo elimination by specific effector cells of an established syngeneic rat moloney virus-induced sarcoma. J Immunol. 1979 Oct;123(4):1772–1777. [PubMed] [Google Scholar]
  8. Fong T. A., Mosmann T. R. The role of IFN-gamma in delayed-type hypersensitivity mediated by Th1 clones. J Immunol. 1989 Nov 1;143(9):2887–2893. [PubMed] [Google Scholar]
  9. Fox B. A., Spiess P. J., Kasid A., Puri R., Mulé J. J., Weber J. S., Rosenberg S. A. In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes. J Biol Response Mod. 1990 Oct;9(5):499–511. [PubMed] [Google Scholar]
  10. Fraker D. L., Langstein H. N., Norton J. A. Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity. J Exp Med. 1989 Sep 1;170(3):1015–1020. doi: 10.1084/jem.170.3.1015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fujiwara H., Fukuzawa M., Yoshioka T., Nakajima H., Hamaoka T. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity. J Immunol. 1984 Sep;133(3):1671–1676. [PubMed] [Google Scholar]
  12. Gajewski T. F., Fitch F. W. Anti-proliferative effect of IFN-gamma in immune regulation. IV. Murine CTL clones produce IL-3 and GM-CSF, the activity of which is masked by the inhibitory action of secreted IFN-gamma. J Immunol. 1990 Jan 15;144(2):548–556. [PubMed] [Google Scholar]
  13. Giovarelli M., Santoni A., Jemma C., Musso T., Giuffrida A. M., Cavallo G., Landolfo S., Forni G. Obligatory role of IFN-gamma in induction of lymphokine-activated and T lymphocyte killer activity, but not in boosting of natural cytotoxicity. J Immunol. 1988 Oct 15;141(8):2831–2836. [PubMed] [Google Scholar]
  14. Greenberg P. D., Cheever M. A., Fefer A. Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes. J Exp Med. 1981 Sep 1;154(3):952–963. doi: 10.1084/jem.154.3.952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Greenberg P. D., Kern D. E., Cheever M. A. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med. 1985 May 1;161(5):1122–1134. doi: 10.1084/jem.161.5.1122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Greenberg P. D. Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ cells: cytolytic T cells can mediate eradication of disseminated leukemia. J Immunol. 1986 Mar 1;136(5):1917–1922. [PubMed] [Google Scholar]
  17. Guerne P. A., Piguet P. F., Vassalli P. Production of interleukin 2, interleukin 3, and interferon by mouse T lymphocyte clones of Lyt-2+ and -2- phenotype. J Immunol. 1984 Apr;132(4):1869–1871. [PubMed] [Google Scholar]
  18. Issekutz T. B. Effects of six different cytokines on lymphocyte adherence to microvascular endothelium and in vivo lymphocyte migration in the rat. J Immunol. 1990 Mar 15;144(6):2140–2146. [PubMed] [Google Scholar]
  19. Issekutz T. B., Stoltz J. M., vd Meide P. Lymphocyte recruitment in delayed-type hypersensitivity. The role of IFN-gamma. J Immunol. 1988 May 1;140(9):2989–2993. [PubMed] [Google Scholar]
  20. Kedar E., Schwartzbach M., Raanan Z., Hefetz S. In vitro induction of cell-mediated immunity to murine leukemia cells. II. cytotoxic activity in vitro and tumor-neutralizing capacity in vivo of anti-leukemia cytotoxic lymphocytes generated in macrocultures. J Immunol Methods. 1977;16(1):39–58. doi: 10.1016/0022-1759(77)90038-2. [DOI] [PubMed] [Google Scholar]
  21. Kelso A., Glasebrook A. L. Secretion of interleukin 2, macrophage-activating factor, interferon, and colony-stimulating factor by alloreactive T lymphocyte clones. J Immunol. 1984 Jun;132(6):2924–2931. [PubMed] [Google Scholar]
  22. Lin Y. L., Askonas B. A. Biological properties of an influenza A virus-specific killer T cell clone. Inhibition of virus replication in vivo and induction of delayed-type hypersensitivity reactions. J Exp Med. 1981 Aug 1;154(2):225–234. doi: 10.1084/jem.154.2.225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Maraskovsky E., Chen W. F., Shortman K. IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells. J Immunol. 1989 Aug 15;143(4):1210–1214. [PubMed] [Google Scholar]
  24. Meltzer M. S. Macrophage activation for tumor cytotoxicity: characterization of priming and trigger signals during lymphokine activation. J Immunol. 1981 Jul;127(1):179–183. [PubMed] [Google Scholar]
  25. Miyatake S., Nishihara K., Kikuchi H., Yamashita J., Namba Y., Hanaoka M., Watanabe Y. Efficient tumor suppression by glioma-specific murine cytotoxic T lymphocytes transfected with interferon-gamma gene. J Natl Cancer Inst. 1990 Feb 7;82(3):217–220. doi: 10.1093/jnci/82.3.217. [DOI] [PubMed] [Google Scholar]
  26. Mulé J. J., Rosenstein M., Shu S., Rosenberg S. A. Eradication of a disseminated syngeneic mouse lymphoma by systemic adoptive transfer of immune lymphocytes and its dependence upon a host component(s). Cancer Res. 1985 Feb;45(2):526–531. [PubMed] [Google Scholar]
  27. Nishihara K., Miyatake S., Sakata T., Yamashita J., Kikuchi H., Kawade Y., Zu Y., Namba Y., Hanaoka M., Watanabe Y. Augmentation of tumor targeting in a line of glioma-specific mouse cytotoxic T-lymphocytes by retroviral expression of mouse gamma-interferon complementary DNA. Cancer Res. 1988 Sep 1;48(17):4730–4735. [PubMed] [Google Scholar]
  28. Oehler J. R., Herberman R. B. Evidence for long-lasting tumor immunity in a syngeneic rat lymphoma model: correlation of in vitro findings with in vivo observations. J Natl Cancer Inst. 1979 Mar;62(3):525–529. doi: 10.1093/jnci/62.3.525. [DOI] [PubMed] [Google Scholar]
  29. Pace J. L., Russell S. W., Torres B. A., Johnson H. M., Gray P. W. Recombinant mouse gamma interferon induces the priming step in macrophage activation for tumor cell killing. J Immunol. 1983 May;130(5):2011–2013. [PubMed] [Google Scholar]
  30. Prat M., Bretti S., Amedeo M., Landolfo S., Comoglio P. M. Monoclonal antibodies against murine IFN-gamma abrogate in vivo tumor immunity against RSV-induced murine sarcomas. J Immunol. 1987 Jun 15;138(12):4530–4533. [PubMed] [Google Scholar]
  31. Prat M., Di Renzo M. F., Comoglio P. M. Characterization of T lymphocytes mediating in vivo protection against RSV-induced murine sarcomas. Int J Cancer. 1983 Jun 15;31(6):757–764. doi: 10.1002/ijc.2910310614. [DOI] [PubMed] [Google Scholar]
  32. Rosenberg S. A., Aebersold P., Cornetta K., Kasid A., Morgan R. A., Moen R., Karson E. M., Lotze M. T., Yang J. C., Topalian S. L. Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med. 1990 Aug 30;323(9):570–578. doi: 10.1056/NEJM199008303230904. [DOI] [PubMed] [Google Scholar]
  33. Rosenstein M., Rosenberg S. A. Generation of lytic and proliferative lymphoid clones to syngeneic tumor: in vitro and in vivo studies. J Natl Cancer Inst. 1984 May;72(5):1161–1165. [PubMed] [Google Scholar]
  34. Schultz R. M., Kleinschmidt W. J. Functional identity between murine gamma interferon and macrophage activating factor. Nature. 1983 Sep 15;305(5931):239–240. doi: 10.1038/305239a0. [DOI] [PubMed] [Google Scholar]
  35. Shu S. Y., Rosenberg S. A. Adoptive immunotherapy of newly induced murine sarcomas. Cancer Res. 1985 Apr;45(4):1657–1662. [PubMed] [Google Scholar]
  36. Spiess P. J., Yang J. C., Rosenberg S. A. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J Natl Cancer Inst. 1987 Nov;79(5):1067–1075. [PubMed] [Google Scholar]
  37. Sugarman B. J., Aggarwal B. B., Hass P. E., Figari I. S., Palladino M. A., Jr, Shepard H. M. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science. 1985 Nov 22;230(4728):943–945. doi: 10.1126/science.3933111. [DOI] [PubMed] [Google Scholar]
  38. Suzuki Y., Orellana M. A., Schreiber R. D., Remington J. S. Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science. 1988 Apr 22;240(4851):516–518. doi: 10.1126/science.3128869. [DOI] [PubMed] [Google Scholar]
  39. Topalian S. L., Kasid A., Rosenberg S. A. Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. Possible mechanisms for immunotherapeutic failures. J Immunol. 1990 Jun 1;144(11):4487–4495. [PubMed] [Google Scholar]
  40. Weber J. S., Rosenberg S. A. Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro. Cancer Res. 1988 Oct 15;48(20):5818–5824. [PubMed] [Google Scholar]
  41. Yamasaki T., Handa H., Yamashita J., Watanabe Y., Namba Y., Hanaoka M. Specific adoptive immunotherapy with tumor-specific cytotoxic T-lymphocyte clone for murine malignant gliomas. Cancer Res. 1984 May;44(5):1776–1783. [PubMed] [Google Scholar]
  42. Yang J. C., Perry-Lalley D., Rosenberg S. A. An improved method for growing murine tumor-infiltrating lymphocytes with in vivo antitumor activity. J Biol Response Mod. 1990 Apr;9(2):149–159. [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES